LIRAGLUTID CIPLA 6mg / ml solution for injection in pre-filled pen medication leaflet

A10BJ02 liraglutide • Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Glucagon-like peptide-1 (GLP-1) analogues

Liraglutide is a medication used for the treatment of type 2 diabetes and obesity. It is a glucagon-like peptide-1 (GLP-1) analog that works by stimulating insulin secretion, reducing glucagon secretion, and slowing gastric emptying, thereby lowering blood sugar levels and reducing appetite.

Liraglutide is administered as a subcutaneous injection, usually once daily, and is used either for blood sugar control in patients with type 2 diabetes or for weight loss in patients with obesity or overweight associated with other conditions (such as hypertension or dyslipidemia).

Side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, or, in rare cases, pancreatitis. It may also cause appetite suppression and weight loss. It is important to use the medication as prescribed by a doctor, and patients should be monitored to prevent complications.

General data about LIRAGLUTID CIPLA 6mg / ml

Substance: liraglutide

Date of last drug list: 01-01-2026

Commercial code: W71578001

Concentration: 6mg / ml

Pharmaceutical form: solution for injection in pre-filled pen

Quantity: 2

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: CIPLA EUROPE NV - BELGIA

Holder: CIPLA EUROPE NV - BELGIA

Number: 16340/2025/01

Shelf life: 2 years-after packing for marketing;after the first opening-1 luna

Other substances similar to liraglutide

Combinations with other substances